63409-12-1
Chemical Structure
Tylvalosin
Synonym(s): Acetylisovaleryltylosin
- CAS No.: 63409-12-1
- Formula:C53H87NO19
- Molecular Weight:1042.25
IUPAC Name: (2S,3S,4R,6S)-6-(((2R,3S,4R,5R,6R)-6-(((4R,5S,6S,7R,9R,11E,13E,15R,16R)-4-acetoxy-16-ethyl-15-((((2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-6-
InChIKey: KCJJINQANFZSAM-HZDSEHBESA-N
SMILES: O[C@@H]1[C@@H](C)O[C@@H](OC[C@H]([C@@H](CC)OC(C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H](OC(CC(C)C)=O)[C@@](O)(C)C3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@H]4C)=O)/C=C(C)/C=C/C4=O)[C@H](OC)[C@@H]1OC
Biological Activity: Tylvalosin (Acetylisovaleryltylo?sin) is an orally active, broad-spectrum macrolide antibiotic with antimicrobial activity. Tylvalosin is an antiviral agent used to study PRRSV infection. Tylvalosin induces apoptosis. Tylvalosin also has anti-inflammatory activity, alleviates oxidative stress, and alleviates acute lung injury by inhibiting NF-κB activation[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tylvalosin | 99.00% | Tylvalosin (Acetylisovaleryltylo?sin) is an orally active, broad-spectrum macrolide antibiotic with antimicrobial activity. Tylvalosin is an antiviral agent used to study PRRSV infection. Tylvalosin induces apoptosis. Tylvalosin also has anti-inflammatory activity, alleviates oxidative stress, and alleviates acute lung injury by inhibiting NF-κB activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tylvalosin-d9 | Tylvalosin-d9 (Acetylisovaleryltylo?sin-d9) is the deuterium labeled Tylvalosin (HY-128423A). Tylvalosin is a third-generation macrolide, with anti-inflammatory property. Tylvalosin decreases the levels of IL-8, IL-6, IL-1β, PGE2, TNF-α and NO, and reduces the inflammatory cells recruitment and activation in mouse acute lung injury model. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Albert Philip Adrian Mockett, et al. Use of tylvalosin as antiviral agent. Patent. WO2008007104.
- [2]. Zhao Z, et al. Tylvalosin exhibits anti-inflammatory property and attenuates acute lung injury in different models possibly through suppression of NF-κB activation. Biochem Pharmacol. 2014 Jul 1;90(1):73-87. [Content Brief]
- [3]. Moges R, et al. Anti-Inflammatory Benefits of Antibiotics: Tylvalosin Induces Apoptosis of Porcine Neutrophils and Macrophages, Promotes Efferocytosis, and Inhibits Pro-Inflammatory CXCL-8, IL1α, and LTB4 Production, While Inducing the Release of Pro-Resolving Lipoxin A4 and Resolvin D1. Front Vet Sci. 2018 Apr 11;5:57. [Content Brief]
